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Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC)
breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is
uncertain. Inconsistencies relate to definitions, incidence, staging and intertumoral heterogeneity. The
primary aim of this systematic review was to compare clinical outcomes after BCS versus mastectomy for
MF and MC cancers, collectively defined as multiple ipsilateral breast cancers (MIBC).
Methods: Comprehensive electronic searches were undertaken to identify complete papers published
in English between May 1988 and July 2015, primarily comparing clinical outcomes of BCS and
mastectomy for MIBC. All study designs were included, and studies were appraised critically using the
Newcastle–Ottawa Scale. The characteristics and results of identified studies were summarized.
Results: Twenty-four retrospective studies were included in the review: 17 comparative studies and seven
case series. They included 3537 women with MIBC undergoing BCS; breast cancers were defined as MF
in 2677 women, MC in 292, and reported as MIBC in 568. Six studies evaluated MIBC treated by BCS or
mastectomy, with locoregional recurrence (LRR) rates of 2–23 per cent after BCS at median follow-up
of 59⋅5 (i.q.r. 56–81) months. BCS and mastectomy showed apparently equivalent rates of LRR (risk ratio
0⋅94, 95 per cent c.i. 0⋅65 to 1⋅36). Thirteen studies compared BCS in women with MIBC versus those
with unifocal cancers, reporting LRR rates of 2–40 per cent after BCS at a median follow-up of 64 (i.q.r.
57–73) months. One high-quality study reported 10-year actuarial LRR rates of 5⋅5 per cent for BCS in
300 women versus 6⋅5 per cent for mastectomy among 887 women.
Conclusion: The available studies were mainly of moderate quality, historical and underpowered, with
limited follow-up and biased case selection favouring BCS rather than mastectomy for low-risk patients.
The evidence was inconclusive, weakening support for the St Gallen consensus and supporting a future
randomized trial.
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Introduction
Breast cancer affects 1⋅7 million women annually world-
wide, the majority of whom are treated surgically1.
Clinical evidence is well established for the treatment
of unifocal cancers by breast-conserving surgery (BCS)
and whole-breast radiotherapy (RT) in preference to
mastectomy2,3. In contrast, there are no a priori random-
ized trials evaluating the clinical safety of BCS for treating
multiple ipsilateral breast cancers (MIBC). MIBC are col-
lectively defined as more than one synchronous ipsilateral
cancer at diagnosis. In a national Association of Breast
Surgery survey of UK breast surgeons in 2015, 91 per cent
of surgeons thought that a randomized trial evaluating the
safety and quality-of-life implications after BCS for MIBC
was clinically important (Z. E. Winters, unpublished data)
Observational studies evaluating treatments for MIBC
have shown wide variation in clinical outcomes. There
have also been wide ranging expert opinions on optimal
surgical treatments3,4. Inherent clinical inconsistencies
include variable definitions, large variation in incidences
depending on the sensitivity of preoperative imaging (for
example mammography versus MRI), underestimating the
tumour load using the current TNM staging classification
and unknown clinical implications of MIBC, where multi-
focal (MF) cancers may be clinically and genetically
distinguishable from multicentric (MC) ones5. These
issues have challenged interstudy comparisons and clinical
evidence regarding treatments for MIBC.
Historically, MF cancers have been defined as more than
one cancer within the same breast quadrant, whereas MC
cancers are widely spaced in different quadrants. MIBC
may also include ductal carcinoma in situ (DCIS) and
invasive breast cancer5. However, these definitions are
problematic, with no breast anatomical boundaries and
variably defined distances of clinically apparently normal
tissue between cancers; MF cancers are foci separated by
40mm or less (or no more than 20mm), and MC cancers
are foci separated by more than 40mm (or over 20mm)
or tumours in different quadrants6–8. According to the
College of American Pathologists guidelines9, character-
ization of only the largest lesion in MIBC is sufficient,
provided that all cancers have the same tumour grade.
Despite this, several authors10,11 have suggested revising
the current TNM staging system12, potentially avoiding
underestimation of the overall disease burden for MIBC.
Recently, Desmedt and colleagues8 suggested that genom-
ically heterogeneous cancers tended to be situated further
apart (MC cancers), whereas those closer together (MF
cancers) showed intertumoral homogeneity. Molecular
characterization of each cancer focus to distinguish
between MC and MF cancers may be important in future
classifications8. Intertumoral heterogeneity in MIBC
has been reported in 11–27 per cent of patients8,13,14.
Generally, evaluation of the largest cancer using standard
immunohistochemical (IHC) biomarkers (oestrogen and
progesterone receptors, human epidermal growth factor
receptor 2 (HER2) and Ki-67) is performed3,9,15. However
in future, the potential to use extended IHC biomarkers
and whole-genome sequencing may increase the recogni-
tion of intertumoral heterogeneity14,16–18, with prognostic
implications19–22.
Clinically occult cancers may remain dormant, or may
be treated adequately by adjuvant whole-breast RT after
BCS8. The incidence of clinically and radiologically
detected MIBC ranges from 10 to 24 per cent of all breast
cancers20–23, increasing with time from earlier to later
studies. This apparent doubling in incidence of MIBC
over the 10 years between 1990 and 2000 may be due in
part to improved breast imaging (digital mammography,
ultrasonography and MRI) and increased screening24.
Standard imaging of MIBC may include digital mam-
mography, ultrasound examination and MRI, with biopsy
confirmation of any additional suspected cancers on
MRI to minimize their misdiagnosis, which occurs in
30 per cent of ‘lesions’24,25. Studies6,10,11,19–21,23,26 are
conflicting on the prognostic implications of MIBC, with
suggestions of increased axillary lymph node involve-
ment latterly using sentinel lymph node biopsy (SLNB),
and with worse overall outcomes than those for unifocal
cancers19,22,23. Increased rates of locoregional recurrence
(LRR)5 and breast cancer events22,23,27,28 secondary to
BCS for MIBC have been reported, but vary widely
across studies. Recently, a clear majority of the St Gallen
expert consensus panel3 expressed the opinion that it was
possible to treat MF and MC cancers with BCS, where
there was margin clearance and whole-breast RT was
planned. However, this opinion was not contextualized to
clinical outcomes specifically differentiating MF and MC
cancers, or comparable outcomes following mastectomy
as the standard of care. Current guidelines are concordant
regarding adjuvant treatments (chemotherapy, endocrine
therapy, targeted therapy and RT) informed by tumour
subtypes3,5.
This systematic review critically appraises the levels of
clinical evidence, and whether these support or weaken
the case on which expert opinion is based in support of
BCS. The primary aim was to compare disease-specific
outcomes following BCS versus mastectomy for treating
MIBC (includingMF andMC cancers). Studies comparing
BCS for treating MIBC and unifocal disease were also
evaluated.
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Methods
A protocol was developed that followed the PRISMA state-
ment for review methods and reporting29. A PICOS (par-
ticipants, interventions, comparators, outcomes and study
designs) sequencewas used to describe the included studies.
In this systematic review, the termMIBC refers to bothMF
andMC cancers.Where individual studies referred specifi-
cally toMF orMC cancers, these definitions were retained.
Literature search strategy
Web-based search engines MEDLINE, Embase,
PsycINFO, ISI Web of Knowledge and Cochrane
databases were interrogated using keywords (Appendix
S1, supporting information). The search was limited to
human studies published in English from May 1988 to
July 2015. Abstracts and conference reports were excluded
owing to difficulties in evaluating incomplete informa-
tion. Duplicate records were excluded. Two independent
reviewers screened titles and abstracts for eligibility using
predetermined criteria. Reference lists of screened articles
and reviews were searched manually to identify further
relevant studies. The intention was to focus on RCTs and
non-randomized longitudinal cohort studies, and this was
extended to include all study designs.
Data extraction
A standardized data pro forma was created including study
design, nature of data accrual, number of centres, years
of data collection, study inclusion and exclusion criteria,
diagnostic methods, clinical outcomes (LRR, disease-free
survival (DFS) and overall survival), duration of follow-up,
pathological details, adjuvant treatment and non-clinical
outcomes (Appendix S2, supporting information). All data
were evaluated independently by two authors, and discrep-
ancies resolved by the senior author.
Inclusion and exclusion criteria and outcomes
Included studies were those evaluating women aged at
least 18 years with invasive cancer and/or DCIS diagnosed
as MIBC before operation or after surgery (histological
diagnosis). Eligible interventions comprised BCS, either
primary or secondary to neoadjuvant treatment. To be
included, studies required a direct comparison of BCS with
mastectomy for MIBC (primary aim), or a comparison of
BCS for MIBC versus BCS for unifocal cancers (secondary
aim). There were no exclusion criteria relating tominimum
numbers of participants or duration of follow-up.
Other inclusion criteria required the study to be pri-
mary research as opposed to audit, and to include a min-
imum of one relevant clinical outcome such as: LRR (local
relapse-free, clinical local recurrence), distant metastasis
(distant disease), DFS (disease-free survival) or overall
survival (breast cancer-specific disease, overall metastases,
breast cancer-specific survival).
Study quality
Risk of study bias was assessed using the
Newcastle–Ottawa scale (NOS)30,31. The NOS com-
prises a semiquantitative assessment of study quality, using
eight separate measures. These measures score the study
based on selection of patients, comparability of groups and
reporting of outcomes. The score ranges from 0 to 9. Stud-
ies scoring 7 or more are considered high quality, those
scoring 4–6 are of moderate quality, and those with a score
of less than 4 are of poor quality. Two reviewers scored each
study independently, with discussion and re-evaluation of
scoring discrepancies resulting in consensus.
Data analysis
Data on recurrence rates were analysed using a fixed-effects
model. Risk ratios and 95 per cent confidence inter-
vals were calculated with Revman 5.3 software (Nordic
Cochrane Centre, Copenhagen, Denmark) and presented
as a forest plot. Heterogeneity among studies was assessed
by means of the I2 statistic.
Results
Study selection
Titles and abstracts of 471 citations were identified elec-
tronically (Fig. 1) After review of 37 full-text articles, 24
primary papers were retained. Of the 13 articles excluded,
six did not report primary research (review articles), three
did not report on surgical interventions, two did not report
on BCS for MIBC and two were not focused on MIBC.
Study design
There were no RCTs and there was a paucity of published
data addressing the primary aim. The 24 studies had retro-
spective observational designs, comprising 17 comparative
studies20–23,27,32–43 and seven case series28,44–49 (Table 1;
Table S1, supporting information). The studies included a
total of 3537 women with MIBC undergoing BCS: 2677
with tumours defined as MF, 292 as MC, and 568 not
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 162–174
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 BCS versus mastectomy n = 4
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Studies included in
quantitative synthesis
(meta-analysis)
n = 6
Fig. 1 Selection of articles for review. MIBC, multiple ipsilateral breast cancers; BCS, breast-conserving surgery
defined as eitherMForMC, but reported asMIBC. Assess-
ment of the observational studies using the NOS showed
that three20,27,43 were of high quality (score at least 7) and
1421–23,32–42 of moderate quality (score 4–6) (Table S2,
supporting information).
Participants
Seventeen studies20,21,27,28,32,34–37,40–42,44,46–49 were from
single centres, four33,38,39,45 involved two centres, and there
were three multicentre studies22,23,43 comprising a regional
cancer registry (British Columbia Cancer Agency)43, a
German regional study group (BRENDA Study Group:
Breast Cancer Care under Evidence-based Guidelines)23
and a substudy within three multicentre RCTs of neoad-
juvant chemotherapy (German Breast Group (Gepar)
trials)22 (Table 1; Table S1, supporting information).
Studies included patients recruited between 1968 and
2010, with only two22,35 including patients treated after
2000. Themedian group size of patients withMIBC receiv-
ing BCS was 61 (i.q.r. 35–169) in comparative studies and
22 (14–43) in case series. Diagnostic methods for evaluat-
ingMIBCwere recorded in six of the seven case series44–49
and nine27,32,33,35–40 of the 17 comparative studies. In
these 15 studies, 258 of 592 patients (43⋅6 per cent) were
diagnosed by postoperative pathology and 294 (49⋅7 per
cent) before surgery: clinical examination (129, 21⋅8 per
cent), radiology (103, 17⋅4 per cent) or undefined meth-
ods (62, 10⋅5 per cent). The remaining 40 patients (6⋅8
per cent) were classified as having MIBC based on lesion
detection at surgery32,38,39. Where preoperative diagnostic
methods were defined, ultrasound imaging was reported in
four27,33,40,46 and MRI in three35,47,49 studies.
Data were collected retrospectively in the case series,
whereas six comparative studies20–22,27,33,43 used a prospec-
tive database to identify patients with MIBC treated by
BCS. In the 11 other comparative studies, data were
derived from postoperative histology reports based
on pathologically determined as opposed to clinically
detected disease. Ataseven and co-workers22 omitted pre-
requisite pathological confirmation of each cancer. Studies
reported varied inclusion criteria for MIBC. Twelve
studies20,23,27,32,34,36,37,40,42,43,48,49 based inclusion on TNM
staging, with three of these23,32,42 mandating inclusion by
size of the largest cancer. Another six studies21,28,39,44,46,47
used the feasibility of BCS to define eligibility. The
remaining studies included: macroscopically separate
tumours33,35,45, synchronous ipsilateral breast cancers on
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 162–174
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Table 1 Summary of study characteristics, treatments and clinical outcomes of primary studies comparing breast-conserving surgery
with mastectomy
No of patients (MF; MC)
Other treatments
Pathology Outcomes
Reference
Study interval
and location
NOS score
Cancers
included
FU (months)*
Group
differences
in CP BCS Mastectomy BCS‡ Mastectomy
Nos et al.32
1983–1989
France
1 centre
NOS 4
n.a.
FU 101 (86–129)
Significant
differences in age
and T category
56 (56; 0)
Radiotherapy,
chemotherapy,
endocrine
IDC 79%,
ILC 13%
132
Radiotherapy,
chemotherapy,
endocrine
IDC 83%,
ILC 8%
5-year LRR: 11%
10-year LRR: 23%
5-year DM: 18%
10-year DM: 28%
5-year OS: 94%
10-year OS: 73%
5-year LRR: 11%
10-year LRR: 14%
5-year DM: 18%
10-year DM: 35%
5-year OS: 89%
10-year OS: 65%
Kaplan et al.33†
1989–2002
USA
2 centres
NOS 4
MIBC, diagnosed
before surgery
FU 45 (1–143)
No significant
differences
36
Radiotherapy,
chemotherapy,
endocrine
IDC 72%,
ILC 19%,
DCIS 8%
19
Radiotherapy,
chemotherapy,
endocrine
IDC 68%,
ILC 21%,
DCIS 11%
5-year LRR: 1 of 36
(3%) (P=0.54)
DM: 1 of 36 (3%)
(P=0⋅20)
OS: 36 of 36 (100%)
5-year LRR: 0 of 19 (0%)
DM: 1 of 19 (5%)
OS: 19 of 19 (100%)
Lim et al.34
1990–2003
South Korea
1 centre
NOS 6
MF
FU 59 (1–177)
Mastectomy:
65 (6–196)
HER2+ (P=0⋅007)
T2 (P=0⋅006)
147 (147; 0)
Radiotherapy,
endocrine
IDC 97%,
ILC 3%
331
Radiotherapy,
endocrine
IDC 96%,
ILC 4%
5-year LRR: 3 of 147
(2.0%) (P=0⋅38)
5-year DFS: 89%
(P=0⋅45)
5-year OS: 93⋅4%
(P=0⋅21)
5-year LRR: 3 of 331
(0⋅9%)
5-year DFS: 92%
5-year OS: 94⋅5%
Kadiog˘lu et al.35
2002–2011
Turkey
1 centre
NOS 5
MF, diagnosed
by histology
FU 55 (10–102)
No. of foci
(P=0⋅001)
LVI (P=0⋅04)
LN positivity
(P=0⋅002)
TNM stage
(P=0⋅01)
HER2+ (P=0⋅03)
119 (119; 0)
Radiotherapy,
chemotherapy,
endocrine
IDC 71%,
ILC 12%
103
Radiotherapy,
chemotherapy,
endocrine
IDC 69%,
ILC 8%
5-year LRR: 6 of 119
(5⋅0%) (P = 0⋅06)
5-year OS: 92%,
median 95 (range
91–99) months
(P<0⋅001)
5-year LRR: 6 of 103
(5⋅8%)
5-year OS: 72%, median
73 (range 68–78)
months
Neri et al.20†
Italy
1991–2005
1 centre
NOS 7
MF diagnosed
before surgery
FU 88 (11–248)
n.a. 36 (36; 0)
Radiotherapy,
chemotherapy
endocrine
155
Radiotherapy,
chemotherapy,
endocrine
7-year LR: 3 of
36 (8%)
7-year LLR: 5 of
36 (14%)
7-year RR: 2 of
36 (6%)
DM: 7 of 36 (19%)
7-year LR: 12 of 155
(7⋅7%)
7-year LLR: 23 of 155
(14⋅8%)
7-year RR: 11 of 155
(7⋅1%)
DM: 42 of 155 (27⋅1%)
Yerushalmi et al.43†
1989–2005
South Korea
5 regional centres
NOS 7
MIBC, diagnosed
before surgery
FU 93
T, N category
(P<0⋅001)
EIC (P<0⋅001)
Positive margins
(P<0⋅001)
300
Radiotherapy,
chemotherapy,
endocrine
IDC 88%,
ILC 12%
887
Radiotherapy,
chemotherapy,
endocrine
IDC 92%,
ILC 6%
17 of 300 (5⋅7%) 58 of 887 (6⋅5%)
*Values are mean (range). All studies were retrospective; †prospective database. ‡P values are for comparison of breast-conserving surgery (BCS) versus
mastectomy. NOS, Newcastle–Ottawa Scale; FU, follow-up; CP, clinical pathology; MF, multifocal; MC, multicentric; n.a., not available; IDC, invasive
ductal cancer; ILC, invasive lobular cancer; LRR, locoregional recurrence; DM, distant metastasis; OS, overall survival; MIBC, multiple ipsilateral breast
cancers; DCIS, preinvasive ductal cancer in situ; HER2, human epidermal growth factor receptor 2; T2, tumour size 20–50mm; DFS, disease-free
survival; LVI, lymphovascular invasion; LN, lymph node; LR, local recurrence; RR, regional recurrence; EIC, extensive preinvasive cancer or DCIS.
Further details of the studies can be found in Tables S1–S3 (supporting information).
gross pathological review over and above microscopy38,
patients with DCIS undergoing BCS41 and recruitment
within the Gepar trials22.
Clinical and pathological characteristics
Significant differences between groups in clinical and
pathological characteristics (age, tumour type, DCIS,
TNM stage, receptor status (oestrogen receptor, pro-
gesterone receptor, HER2), lymphovascular invasion,
margins) were reported in four studies32,34,35,43 of BCS
versus mastectomy for MIBC, and in four studies27,37,39,43
of BCS for MIBC versus unifocal cancers (Table S3, sup-
porting information). Intergroup comparisons showed
that prognostic factors were worse among patients who
underwent mastectomy than those who underwent BCS,
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 162–174
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and among those with MIBC compared with those who
had unifocal disease. Yerushalmi and colleagues43 used a
matched analysis (3 : 1) of clinicopathological character-
istics, accounting for three times more unifocal cancers
than MIBC. Retrospective study designs made it difficult
to compare clinical data, compounded by significantly
larger numbers of unifocal cancers20–23,41,42. With the
exception of one recent study22, no studies reported
the distribution of molecular subtypes (luminal A, lumi-
nal B, non-luminal HER2, basal and triple-negative).
Overall, five studies23,27,34,35,43 used statistical regression
methodologies adjusting for baseline co-variables.
Definitions of MIBC
Definitions of MF or MC tumours were described in
2120–23,27,28,32,34,35,37,39–49 of 24 studies. Eleven studies
assessed MIBC as a single group33,36–40,42–45,47, and
1320–23,27,28,32,34,35,41,46,48,49 evaluated BCS in MF and
MC cancers separately (Table 1; Table S3, supporting
information).
Clinical outcomes
Clinical outcomes are summarized inTable 1 and detailed in
Table S4 (supporting information). Eleven21,22,27,36–43 of 17
comparative studies evaluated clinical outcomes of BCS for
both MIBC and unifocal cancers; only four studies23,32,33,35
exclusively compared BCS with mastectomy for MIBC.
Lim and colleagues34 and Neri et al.20 evaluated outcomes
of bothMIBC and unifocal cancers independent of the type
of surgery. Of the 24 studies, five20,23,27,32,43 reported actu-
arial 10-year clinical outcomes, despite 10 years being the
optimal period of follow-up according to the Association of
Breast Surgery guidelines50. Overall, the studies reported a
median follow-up of 60 (i.q.r. 53–73) months.
Interventions
Various descriptions of the type of BCS were used
(Table 1; Table S1, supporting information). Fourteen
studies21–23,28,32,34,35,39–44,47 referred to BCS and
three36–38 to wide local excision. Others referred to partial
mastectomy20,45, quadrantectomy46,48, segmentectomy27
or lumpectomy33,49. The extent of acceptable micro-
scopic margin status following BCS was defined in
1821–23,27,28,33–41,44–46,48 actuarial studies. Differing
definitions of microscopically clear radial cancer margins
were used. Commonly, this comprised radial margins of
at least 1mm23,27,28,33,34,40,44,48, although two studies5,46
used 2mm or more and one39 required margins of at least
5mm. Other studies referred to ‘grossly excised’36–38,
‘tumour-free margins’22 and ‘clear at the inked margin’41.
In one study21, margins were defined as ‘close’ if less than
2mm from the ‘cut edges’, and another35 based margin
re-excisions on clinicians’ assessments.
Adjuvant treatments
Adjuvant radiotherapy
All 24 studies reported using postoperative RT after
BCS. Completion of RT after BCS was described in 15
studies20,21,23,27,32,35,36,38–41,43–46. In three studies22,37,42
it was not possible to define the extent of RT or dose
fractionation used. The RT regimen was described in
11 studies23,32,36–40,44–47, with a tumour bed boost RT
reported in eight23,32,36,37,39,40,45,46 of these. There was no
mention of more than one lumpectomy bed receiving a
tumour bed RT boost in MC cancers; however, there were
only 223 MC cancers treated by BCS (Table 1; Table S1,
supporting information).
Adjuvant endocrine therapy
Twenty studies20–23,27,28,32–35,39,41–49 reported using adju-
vant endocrine treatments. Eighteen20,21,27,28,32–35,39,41–49
reported patient compliance for endocrine therapy,
with a median of 68 (i.q.r. 43–87) per cent. Four
studies34,47–49 reported endocrine treatment of oestrogen
receptor-positive cancers, with a median compliance rate
of 92 (78–96) per cent.
Adjuvant chemotherapy
Twenty studies20,22,23,27,28,32,33,35,37–40,42–49 described the
use of chemotherapy, with 18 reporting percentages
of patients who received it; this varied widely. Three
studies22,39,40 reported that all patients received some
form of chemotherapy. The overall median per-
centage of patients receiving chemotherapy was 57
(i.q.r. 43–77) per cent20,22,27,28,32,33,35,38–40,42–49. Eight
studies22,35,38–40,44,45,47 described chemotherapy sched-
ules and proportions of women treated, and 11
others20,21,27,28,32,33,42,43,46,48,49 reported proportions of
patients alone, without chemotherapy regimens. Only two
studies22,40 described neoadjuvant chemotherapy.
Clinical cancer outcomes in cohort studies
Reported clinical outcomes varied widely regarding clini-
cal endpoints and duration of follow-up (Table 1; Table S4,
supporting information). Clinical outcomes reported were:
LRR20–22,27,32–43, overall survival20,27,32–35,38,40,43, occur-
rence of distant metastases20,32,33,36 and DFS22,23,27,34.
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Kaplan et al.33
Lim et al.34
Neri et al.20
Nos et al.32
Yerushalmi et al.43
Reference BCS
6 of 119
1 of 36
3 of 147
5 of 36
6 of 56
17 of 300
38 of 694
6 of 103
0 of 19
3 of 331
23 of 155
15 of 132
58 of 887
105 of 1627
11·1
1·3
5·3
16·7
16·8
48·8
100·0
0·87 (0·29, 2·60)
1·62 (0·07, 38·00)
2·25 (0·46, 11·02)
0·94 (0·38, 2·29)
0·94 (0·39, 2·30)
0·87 (0·51, 1·46)
0·94 (0·65, 1·36)
Mastectomy Weight (%) Risk ratio Risk ratio
Total
Heterogeneity: χ2 = 1·39, 5 d.f., P = 0·93; I2 = 0%
0·01 0·1 1 10
Favours mastectomyFavours BCS
100
Test for overall effect: Z = 0·31, P = 0·76
Kadioglu et al.35
Fig. 2 Risk ratio for locoregional recurrence after breast-conserving surgery (BCS) versus mastectomy. An inverse-variance fixed-effect
model was used for meta-analysis. Risk ratios are shown with 95 per cent confidence intervals. Reference 23 was not included in this
analysis as no raw data were available
Eleven studies21,32–40,42 reported outcomes at 5 years or
just over; three32,41,43 reported outcomes at 5 and 10 years;
one23 reported at 10 years only; and the other three studies
reported outcomes at 3 years22, 7 years20 and 9 years27.
The median duration of follow-up in all studies was 60
(i.q.r. 53–73) months.
Clinical cancer outcomes in case series
Six28,44–47,49 of seven case series evaluated clinical out-
comes after BCS for MIBC with rates of ‘local recurrences’
(LRR, local relapse-free and cumulative local events) rang-
ing from 0 to 5⋅1 per cent over a median follow-up of 53
(i.q.r. 34–72)months (Table S4, supporting information).
The 5-year LRR data were weaker, with Gentilini and
colleagues28 reporting a 6-year actuarial LRR rate of 5⋅1
per cent (24 of 476) after BCS, without a comparator group.
Distant metastasis rates ranged from 4⋅5 to 11 per cent
during follow-up. Median overall survival rates in four
studies28,44,48,49 ranged from 89 to 100 per cent.
Clinical cancer outcomes after breast-conserving
surgery versus mastectomy for MIBC
Six20,32–35,43 of seven studies reported clinical outcomes
for BCS versus mastectomy for MIBC, which was the pri-
mary aim of the review, with a median follow-up of 59⋅5
(i.q.r. 56–81)months (Table 1; Table S4, supporting infor-
mation). The largest of the seven studies was part of the
multicentre BRENDA cohort study23, but did not pro-
vide raw data for comparison. This was scored as having
moderate quality based on analyses of clinical subgroups,
judged to be adherent to German guidelines or not.
Adherence to guidelines meant that BCS was contraindi-
cated forMC cancers23. Non-conformance with guidelines
resulted in 12⋅9 per cent of MC cancers (60 of 464) being
treated with BCS, compared with 46⋅8 per cent (217 of
464) undergoing mastectomy23. LRR was reported in five
studies20,32–35, distant metastases in three20,32,33, overall
survival in four32–35 and DFS in two23,34.
Local recurrence
Six studies20,32–35,43 reported LRR rates ranging from 2
to 23 per cent after BCS, with apparently similar rates of
LRR for BCS compared with mastectomy (risk ratio 0⋅94,
95 per cent c.i. 0⋅65 to 1⋅36) (Fig. 2). There was no het-
erogeneity in these studies, which may reflect similar case
selection biases with surgeons choosing BCS for low-risk
patients and mastectomy for high-risk cases. Overall, the
results should be viewed with caution because they may be
compromised by study quality.
The historical study of Yerushalmi and colleagues43
reported the potential clinical equivalence of mastectomy
in 887 patients compared with standard BCS in 300
patients, with 10-year LRR rates of 6⋅5 per cent (58 of
887) versus 5⋅7 per cent (17 of 300) respectively (P= 0⋅95).
Five-year LRR rates of MIBC in this study were 4⋅5 per
cent after mastectomy versus 2⋅5 per cent after BCS43.
Survival
Wolters and colleagues23 concluded that treatment of
MF cancers according to German guidelines by BCS
(683 of 1398, 48⋅9 per cent) versus mastectomy (329 of
1398, 23⋅5 per cent) showed no significant differences in
5-year recurrence-free survival. Neri and co-workers20
showed that MF cancers were a significant independent
predictor of worse breast cancer-specific survival for
BCS (hazard ratio (HR) 3⋅88, 95 per cent c.i. 1⋅06 to
14⋅12; P= 0⋅026) and mastectomy (HR 2⋅72, 1⋅15 to 6⋅48;
P= 0⋅023). Kadiog˘lu et al.35 reported significantly better
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5-year survival of 92 per cent (median 95 (range 91–99)
months) after BCS in 119 patients, compared with 72 per
cent (median 73 (68–78) months) after mastectomy in 103
patients (P< 0⋅001). Multivariable analyses in the latter
study, accounting for intergroup differences, subsequently
showed no significant effects on outcomes between types
of surgery (P= 0⋅07)35. Similarly, Nos and colleagues32,
Kaplan and co-workers33 and Lim et al.34 reported no
differences in overall survival, DFS or distant metastases
by type of surgery.
Clinical outcomes after breast-conserving surgery
for MIBC versus unifocal cancers
Table S4 (supporting information) provides data on out-
comes after BCS for MIBC versus unifocal cancers.
Local recurrence
Twelve of 13 studies reported LRR rates after BCS for
MIBC ranging from 2 to 40 per cent at a median follow-up
of 64 (i.q.r. 57–73)months. Two historical studies36,37
showed significantly higher LRR rates after BCS forMIBC
compared with those for unifocal cancers. More recently,
Chung et al.27 reported significantly worse 9-year LRR
rates of 6⋅1 per cent (10 of 164) in patients with MIBC
compared with 0⋅6 per cent (6 of 999) in patients with uni-
focal disease (P= 0⋅001). Using a matched-pair analysis,
Yerushalmi and colleagues43 reported equivalent actuarial
10-year local recurrence rates of 5⋅6 per cent for MIBC
(MF and MC) among 300 patients treated by BCS ver-
sus 4⋅3 per cent for unifocal cancer among 11 683 patients
after BCS (HR 1⋅09, 95 per cent c.i. 0⋅55 to 2⋅16; P= 0⋅78).
Furthermore, no differences were shown for 10-year LRR
between the groups (Table S4, supporting information).
Neri et al.20 reported significantly worse 7-year LRR for
MIBC treated by BCS (2 of 36, 6 per cent) compared
with BCS for unifocal cancers (8 of 491, 1⋅6 per cent)
(P= 0⋅050). This study reported 304 disease recurrences at
a median follow-up of 7⋅3 years (range 11–248 months),
with a median time to relapse of 32 months, and 172 deaths
from breast cancer20.
Survival
Nine-year DFS was reported in two studies27,34 (Table S4,
supporting information). Chung and co-workers27
reported a significantly worse 9-year DFS rate of 89⋅3
per cent (14 breast cancer-related events among 164
patients) for MIBC treated by BCS versus 97⋅7 per cent
(17 of 999) following BCS for unifocal cancers, with a
HR of 5⋅86 (95 per cent c.i. 2⋅57 to 13⋅3; P< 0⋅001) in
multivariable analysis. A substudy22 within the GeparTrio
randomized trials evaluated the impact of neoadjuvant
chemotherapy on clinical outcomes of patients with uni-
focal, MF and MC cancers. The choice of either BCS
or mastectomy was based on clinical cancer responses
and the surgeon’s discretion. This substudy demonstrated
that 5-year local relapse-free survival (LRFS) rates in all
patients were significantly adversely affected by focality;
MC cancers alone had the worst LRFS rates of 90⋅4 per
cent, compared with 95⋅1 per cent for MF and 92⋅9 per
cent for unifocal cancers. Lower LRFS rates persisted for
MC cancers after mastectomy (P= 0⋅030), although this
group presented with significantly worse disease in terms
of TNM stage and HER2 positivity (P< 0⋅001)22. Survival
outcomes (LRFS) were not inferior for MC (P= 0⋅844)
and MF (P= 0⋅430) cancers compared with unifocal can-
cers after complete pathological responses to neoadjuvant
chemotherapy22. Neri and colleagues20 identified MIBC
as a significant independent prognostic factor for breast
cancer-specific survival (HR 1⋅64, 95 per cent c.i. 1⋅05
to 2⋅57; P= 0⋅029) using multivariable analyses. Overall
actuarial breast cancer-specific survival rates (independent
of type of surgery) for MIBC were 89⋅7 per cent at 5 years
and 79⋅8 per cent at 10 years.
Distant metastases were reported in two articles20,36.
Leopold et al.36 reported a 5-year rate of distant metastasis
of 40 per cent (4 of 10) for MIBC treated by BCS. In both
papers, distant disease was more common in the MIBC
group. The results reported byNeri and co-workers20 were
statistically significant (19 versus 11⋅2 per cent for MIBC
versus unifocal cancers respectively; P= 0⋅030).
Overall survival was reported in six studies20,27,34,38,40,43.
Two studies demonstrated significantly worse survival
for MIBC compared with unifocal cancers at a mean
follow-up of 88 months (HR 3⋅88, 95 per cent c.i. 1⋅06 to
14⋅12; P= 0⋅020)20 and 112months (85⋅8 versus 98⋅4 per
cent; P< 0⋅001)27. Of the remaining four studies, two34,38
reported worse outcomes, and two40,43 better outcomes
for MIBC, with no significant differences. Although not
statistically significant, a further six studies21,38,39,41–43
reported trends towards worse outcomes after BCS for
MIBC compared with unifocal cancers.
Discussion
This systematic review attempted to appraise the pub-
lished literature critically regarding the impact of BCS
in treating MIBC, compared with the standard of mas-
tectomy with or without breast reconstruction. Overall,
there was limited evidence of moderate quality support-
ing the clinical equivalence of BCS versus mastectomy for
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treating MIBC. Factors limiting the quality of evidence
were study designs, heterogeneous clinical outcomes, and
few if any representative studies of use of BCS to treat
MC tumours compared with MF cancers. The inclusion of
exclusively pathological diagnosis in some studies and the
complexity of surgical case selection were major limiting
factors inherent in the study designs. Other factors were
non-comparability of statistical methodologies, low patient
numbers by type of surgery (particularly for MC cancers)
and limited duration of follow-up. In the context of current
treatments, most studies were historical, with poor report-
ing of adjuvant chemotherapy22. Two studies22,40 evalu-
ated neoadjuvant chemotherapy and BCS in MIBC. Most
did not address the primary aim of this review, but com-
pared BCS for MIBC versus unifocal cancers. The appar-
ent lack of significant intergroup differences in the rates of
LRR may allow clinical equipoise and support the ratio-
nale for a randomized trial. A National Institute for Health
Research (NIHR)-funded randomized trial would evalu-
ate the non-inferiority in terms of LRR after BCS for MF
and/or MC cancers (MIBC) compared with mastectomy.
Most studies included in this review were at high risk
of bias30,31,51,52. Although one-quarter of studies used a
prospective database, none of these published their pro-
tocols or defined their core clinical outcome sets52,53, or
reported study size calculations for the surgical groups54.
Other markers of study quality were lacking, such as ethical
approvals and conflicts of interest30,31,51.
Older studies did not report therapeutic mammaplasty
(TM) techniques55–57. TM as a form of BCS for treating
unifocal cancers has become more common over the past
5 years. However, evidence is lacking for its use in the
treatment of MIBC55–57. TM techniques comprise either
extended breast tissue excisions for cancer(s) with simple
reapproximation of breast tissue (level 1 reconing) or a
therapeutic reduction mammaplasty (level 2)56,57. Cur-
rently, TM is the standard best practice for optimizing
cosmetic outcomes after extended breast tissue excisions
relative to breast volume. Recently, a small case series58
(68 patients) describing BCS for 20 patients with MF
cancers was reported. In principle, treating MC cancers
using two or more separate wide local excisions com-
bined with TM merits future investigation, particularly
in the context of RT boost(s) to one or more tumour
beds. A meta-analysis56 of a non-randomized comparison
between 3165 TM procedures with standard BCS in 5494
patients with unifocal cancers showed that the former
significantly reduced rates of cancer margin positivity
(P< 0⋅001) and surgical re-excisions (P< 0⋅001). Recently,
the St Gallen panel2 recommended a minimal accept-
able surgical margin of ‘no ink on invasive tumour or
DCIS’. Other interventions significantly reducing intra-
operative tumour margin positivity have been described:
digital specimen radiology (P= 0⋅012 for digital versus
conventional mammography)59, tumour margin cavity
shaves60 and real-time cancer margin assessments61,62.
Ataseven and colleagues22 reported that neoadjuvant
chemotherapy-induced pathological complete cancer
response rates increased the surgical options for BCS
without compromising clinical outcomes, an approach
requiring future investigation. Future TM approaches for
treating MIBC should recommend standardized operat-
ing procedures, involving tumour bed clips to facilitate
image-guided RT63–69. A minority of studies (8 of 24)
in the present review referred to tumour bed boost RT
following BCS for MIBC. The feasibility of administering
one or more tumour bed RT boosts after TM in MC
cancers will be evaluated in future63,69.
MIBC may more frequently be associated with
poor prognostic factors compared with unifocal
disease5,20,22,23,26. Coombs and Boyages10 recommended
using aggregate cancer dimensions, thereby upstagingmost
MIBC to more advanced stages, with rates of lymph node
positivity stage-for-stage comparable to those of unifocal
cancers. Positive lymph node involvement was reported in
44–50 per cent of MIBC cases, compared with 38 per cent
of unifocal cancers5,10,20,23,67,70. Dual-localization SLNB
is accurate diagnostically in MIBC70. A subset of women
with MIBC (342, 8⋅5 per cent) in the European Organisa-
tion for Research and Treatment of Cancer 10981-22023
AMAROS (After Mapping of the Axilla: Radiotherapy
Or Surgery) trial had a 51 per cent rate of SLNB posi-
tivity, compared with 28 per cent of those with unifocal
cancers70,71.
Clinical surveillance informing cancer outcomes should
optimally extend to at least 10 years2,3. The Association of
Breast Surgery guidelines50 recommend a target of 5-year
breast cancer LRR rates of 5 per cent or less from diag-
nosis. In future studies, the primary outcome measure
for evaluating the impact of extent of surgery in MIBC
should be 5-year LRR, ideally with follow-up to 10 years72,
with disease-specific and all-cause mortality as important
secondary outcomes53,72. The results of meta-analyses72
including a total of 10 800 patients from 17 randomized
trials of RT versus no RT after BCS underscore this; RT
reduced the 10-year risk of any first recurrence (LRR and
distant) by 16 per cent and breast cancer death by 4 per
cent. Yerushalmi and colleagues43 reported a 5-year LRR
rate for MIBC of 2⋅5 per cent after BCS compared with
4⋅5 per cent after mastectomy. The discordant LRR rates in
favour of BCS suggest biased case selection, with clinically
more aggressive disease selected for mastectomy. A similar
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phenomenon is likely in six reported studies that compared
LRR rates in women with MIBC treated with BCS ver-
sus mastectomy and were analysed here using a forest plot;
this analysis showed no intrastudy heterogeneity and no
apparent effect by type of surgery. Preliminary calculations
suggest that, in future, comparable surgical groups should
comprise at least 1000 patients each, based on predicted
5-year LRR rates of 2⋅5 per cent43, highlighting that the
currently available studies were underpowered.
Some of the reviewed studies22,27 reported worse DFS
and overall survival for MIBC than for single cancers, yet
other studies21,43 noted similar outcomes. MC cancers (but
not MF cancers) were distinguished by significantly worse
overall survival (P= 0⋅009) and DFS (P< 0⋅001) com-
pared with unifocal cancers22. However, this was negated
by a complete pathological response after neoadjuvant
chemotherapy, independent of type of surgery22. Similarly,
Wolters et al.23 reported a significant association between
MIBC and relapse-free survival in a study of 1862 MIBC
compared with 7073 unifocal cancers (P= 0⋅007); however,
this finding related to clinical non-adherence to German
guidelines. Weissenbacher and colleagues19 confirmed a
significant association between MIBC and overall breast
cancer recurrence (P= 0⋅001) in matched-pair multivari-
able analyses ofMIBC comparedwith unifocal cancers (288
in each group). These conflicting reports support a future
review of current TNM staging for MIBC.
Molecular subtyping in breast cancers provides thera-
peutic and prognostic stratification3,17. There is limited
evidence on associations between MIBC and five molec-
ular subtypes, compared with the subtype distribution in
unifocal cancers5. A comprehensive IHC subtyping algo-
rithm (six biomarkers) that can distinguish luminal B from
luminal A cancers, and basal from triple-negative disease,
has potential clinical implications15,17,18. Luminal can-
cers had a lower risk of 5-year LRR than HER2-positive
or triple-negative unifocal disease after BCS in 12 500
patients73. Ataseven and co-workers22 reported increased
associations between oestrogen receptor-positive and
HER2-positive genotypes in MIBC, compared with uni-
focal cancers (P< 0⋅001). Similarly, Moon et al.74 reported
fewer triple-negative MIBC than unifocal cancers. Lynch
and colleagues21 showed no significant associations
between MIBC (906 patients) and molecular subtypes.
Given the growing appreciation of intertumoral hetero-
geneity in MIBC, molecular characterization of a single
focus may underestimate the molecular landscape12. Stan-
dard phenotyping and genotyping of each cancer in MIBC
should underpin future treatment recommendations.
The true biological and clinical significance of MIBC
remains uncertain, with current expert consensus based
on limited evidence. The studies reviewed here have his-
torical limitations and were not adequately powered for
conclusive treatment recommendations to be drawn based
on LRR or survival after BCS compared with mastec-
tomy. Meta-analyses of existing historical prospective data
sets or early randomized trials are likely to be beset by
poor-quality data on pathological focality. Despite the
potential for use of TM to treat MIBC, the evidence base
for readily adopting this treatment is poor. Valuable data
on 5-year effect size for LRR could derive from a current
registry study (ACOSOG (American College of Surgeons
Oncology Group) Z11102)4,75. Based on this, an interna-
tional collaboration guided by the IDEAL (Idea, Devel-
opment, Exploration, Assessment, Long-term Follow-up)
framework51 has suggested the need for a multicentre ran-
domized trial (MIAMI trial)75. This trial should use a prag-
matic classification ofMF andMC cancers. In addition, the
similarity or heterogeneity of genomic profiling for indi-
vidual cancers is likely to supersede existing anatomical or
surgical definitions of MIBC in the future.
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